Combined temozolomide and sunitinib treatment leads to selection of large, high-flow, therapy-resistant glioma vessels by aggravating pericyte-mediated resistance mechanisms via angiopoetin–Tie 2 and delta-like-4 (Dll4)/notch signaling [4]. Here, DLL4 is linked to central nervous system cancer.